DMD and Duchenne muscular dystrophy: However, in some gene therapy scenarios, in order to deliver a dystrophin construct containing the majority of functional motifs to either skeletal muscle stem cells [11,12] ex vivo, or into muscles of animal models of DMD via direct injection [13], small but ubiquitously-expressed promoters have usually been used.